

# Jamunarani Veeraraghavan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6952949/publications.pdf>

Version: 2024-02-01

58  
papers

1,405  
citations

331259

21  
h-index

344852

36  
g-index

60  
all docs

60  
docs citations

60  
times ranked

2475  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer. Cancer Research, 2022, 82, PD8-06-PD8-06.	0.4	1
2	Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of <i>HER</i> and <i>PIK3CA</i> mutations and development of new treatment strategies and study models. Cancer Research, 2022, 82, P4-01-01-P4-01-01.	0.4	1
3	A Novel Neoplastic Fusion Transcript, <i>RAD51AP1-DYRK4</i> , Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers. Clinical Cancer Research, 2021, 27, 785-798.	3.2	11
4	Abstract PD3-09:HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models. , 2021, , .		2
5	Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clinical Cancer Research, 2021, 27, 2648-2662.	3.2	4
6	Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC). , 2021, , .		0
7	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 4870-4882.	3.2	49
8	Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. Npj Breast Cancer, 2021, 7, 63.	2.3	4
9	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. Journal of the National Cancer Institute, 2020, 112, 46-54.	3.0	97
10	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clinical Cancer Research, 2020, 26, 738-745.	3.2	31
11	Towards personalized treatment for early stage HER2-positive breast cancer. Nature Reviews Clinical Oncology, 2020, 17, 233-250.	12.5	166
12	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 821-827.	3.2	40
13	Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Research, 2020, 22, 84.	2.2	18
14	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2020, 84, 101965.	3.4	92
15	Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models. Cancer Research, 2020, 80, 1911-1911.	0.4	8
16	Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer. , 2020, , .		2
17	A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).. Journal of Clinical Oncology, 2020, 38, 1011-1011.	0.8	4
18	Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
19	Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer. , 2020, , .		0
20	Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer. , 2020, , .		0
21	Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2318-2330.	1.5	41
22	A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. <i>Annals of Oncology</i> , 2019, 30, 927-933.	0.6	37
23	FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26823-26834.	3.3	103
24	The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. <i>British Journal of Cancer</i> , 2019, 120, 331-339.	2.9	48
25	Molecular Mechanisms of Endocrine Resistance. <i>Cancer Drug Discovery and Development</i> , 2019, , 265-307.	0.2	5
26	Abstract 4757: Targeting the mevalonate pathway in HER2+breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy. , 2019, , .		0
27	Abstract 376: Therapeutic role of<i>ESR1</i>-<i>CCDC170</i> gene fusion in breast cancer endocrine resistance. , 2019, , .		0
28	Abstract 4474: Novel neoplastic RAD51AP1-DYRK4 fusion transcript in aggressive luminal breast cancers. , 2019, , .		0
29	Abstract 4827: The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive<i>in vivo</i> breast cancer models. , 2019, , .		0
30	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1025-1025.	0.8	3
31	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/O23 and PAMELA trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 509-509.	0.8	10
32	Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies. , 2018, , .		0
33	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5123-5134.	3.2	85
34	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. <i>Breast</i> , 2017, 34, S19-S26.	0.9	46
35	Abstract 1223: Evaluation of the dual p38/NLK kinase inhibitor as potential new therapeutic agent for tamoxifen-resistant breast cancer. , 2017, , .		0
36	Abstract 5741: Evaluating the role of recurrentESR1-CCDC170fusion in breast cancer endocrine resistance. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
37	Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 219-232.	1.1	40
38	Amplification of <i>TLK2</i> Induces Genomic Instability via Impairing the G2/M Checkpoint. <i>Molecular Cancer Research</i> , 2016, 14, 920-927.	1.5	21
39	Comprehensive functional analysis of the tousel-like kinase 2 frequently amplified in aggressive luminal breast cancers. <i>Nature Communications</i> , 2016, 7, 12991.	5.8	45
40	Abstract P1-07-07: Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers. , 2015, , .		0
41	Abstract 3032: Genomic deregulation and therapeutic role of the cell-cycle kinase TLK2 in more aggressive breast cancers. , 2015, , .		0
42	Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. <i>Nature Communications</i> , 2014, 5, 4577.	5.8	112
43	Inflammatory Signature after Low Dose $\hat{I}^3$ -Radiation in Mice Brain and Gut: Switch from Therapeutic Benefit to Inflammation. <i>European Journal of Inflammation</i> , 2013, 11, 405-418.	0.2	0
44	Low-dose $\hat{I}^3$ -radiation-induced oxidative stress response in mouse brain and gut: Regulation by NF $\hat{I}^B$ -MnSOD cross-signaling. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2011, 718, 44-55.	0.9	42
45	Irreversible EGFR Inhibitor EKB-569 Targets Low-LET $\hat{I}^3$ -Radiation-Triggered Rel Orchestration and Potentiates Cell Death in Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2011, 6, e29705.	1.1	14
46	Impact of Curcumin, Raspberry Extract, and Neem Leaf Extract on Rel Protein-Regulated Cell Death/Radiosensitization in Pancreatic Cancer Cells. <i>Pancreas</i> , 2011, 40, 1107-1119.	0.5	54
47	Curcumin Regulates Low-Linear Energy Transfer $\hat{I}^3$ -Radiation-Induced NF $\hat{I}^B$ -Dependent Telomerase Activity in Human Neuroblastoma Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1206-1215.	0.4	39
48	Radiation-triggered Tumor Necrosis Factor (TNF) $\hat{I}^{\pm}$ -NF $\hat{I}^B$ Cross-signaling Favors Survival Advantage in Human Neuroblastoma Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 21588-21600.	1.6	60
49	Abstract 2500: Radiosensitizing effects of neem leaf extract in human neuroblastoma xenograft is through modulation of apoptotic pathway. , 2011, , .		1
50	Abstract 4203: EF24, a novel curcumin analogue inhibits oncogenic activation induced by radiation abscopal effect in distant mice lungs. , 2011, , .		0
51	Abstract 574: Mechanism of radiation-induced bystander effect: Role of NF $\hat{I}^{\gamma}$ pathway. , 2011, , .		0
52	Neem leaf extract induces radiosensitization in human neuroblastoma xenograft through modulation of apoptotic pathway. <i>Anticancer Research</i> , 2011, 31, 161-70.	0.5	21
53	Abstract 1407: Mechanistic regulation of NF $\hat{I}^B$ dependent radioprotection in human neuroblastoma. , 2010, , .		0
54	Abstract 1402: Molecular basis for soy isoflavone genistein in the prevention of posttreatment recurrence of neuroblastoma. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 5547: EF24 attenuates radiation-regulated eNOSâ†’NO-dependent NFÎ±B-mediated matrix metalloproteinases in human neuroblastoma. , 2010, , .		0
56	Abstract 486: Abscopal effect of low-LET ionizing radiation on Rel protein signal transduction. , 2010, , .		0
57	NFÎ±B activity and transcriptional responses in human breast adenocarcinoma cells after single and fractionated irradiation. Cancer Biology and Therapy, 2009, 8, 765-773.	1.5	27
58	NFÎ±B Signaling Related Molecular Alterations in Human Neuroblastoma Cells after Fractionated Irradiation. Journal of Radiation Research, 2009, 50, 311-324.	0.8	17